Profile
Manuel Opitz is the founder of Mecuris GmbH, founded in 2016, where he holds the title of Expert Digital Transformation.
He is also the founder of deepeye Medical GmbH, founded in 2021, where he currently holds the title of Chief Executive Officer.
Manuel Opitz active positions
| Companies | Position | Start |
|---|---|---|
Mecuris GmbH
 Mecuris GmbH Commercial Printing/FormsCommercial Services Mecuris GmbH operates a software platform for automatic generation of patient-customized orthoses and prosthetic designs. The company was founded by Manuel Opitz, Wolf-Peter Werner, Felix Gundlack, Jannis Breuninger and Simon Weidert and is headquartered in Munich, Germany. | Founder | 21/06/2016 |
Deepeye Medical GmbH
 Deepeye Medical GmbH Information Technology ServicesTechnology Services Deepeye Medical GmbH is a German medical company that aims to address the issue of millions going blind every year despite effective retinal therapy. The private company is located in Germany. The company's co-founders have developed a 2nd-opinion-approach using AI to scale their solution. The company also offers Deepeye® research, which unlocks the future of clinical studies. | Chief Executive Officer | 31/12/2020 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Mecuris GmbH
Mecuris GmbH Commercial Printing/FormsCommercial Services Mecuris GmbH operates a software platform for automatic generation of patient-customized orthoses and prosthetic designs. The company was founded by Manuel Opitz, Wolf-Peter Werner, Felix Gundlack, Jannis Breuninger and Simon Weidert and is headquartered in Munich, Germany. | Commercial Services |
Deepeye Medical GmbH
Deepeye Medical GmbH Information Technology ServicesTechnology Services Deepeye Medical GmbH is a German medical company that aims to address the issue of millions going blind every year despite effective retinal therapy. The private company is located in Germany. The company's co-founders have developed a 2nd-opinion-approach using AI to scale their solution. The company also offers Deepeye® research, which unlocks the future of clinical studies. | Technology Services |
- Stock Market
- Insiders
- Manuel Opitz
